Navigation Links
Idera Pharmaceuticals Announces Presentations of Preclinical Data,on New Potential Oncology Applications of its TLR9 Agonists at AACR

g statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated by such forward-looking statements, including whether products based on Idera's technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether the Company will complete enrollment of clinical trials or announce trial results in the time expected; whether, if the Company's products receive approval, they will be successfully distributed and marketed; whether the results of preclinical studies such as those described in this press release will be indicative of results that may be obtained in clinical trials; whether the Company's collaborations with Novartis and Merck will be successful; whether the patents and patent applications owned or licensed by Idera will protect the Company's technology and prevent others from infringing it; whether Idera's cash resources will be sufficient to fund product development and clinical trials; and such other important factors as are set forth under the caption "Risk Factors" in Idera's Annual Report on Form 10-K filed on March 30, 2007, which important factors are incorporated herein by reference. Idera disclaims any intention or obligation to update any forward-looking statements.

Nexavar(R) is a registered trademark of Onyx Pharmaceuticals and Bayer Corporation.

Contact

Idera Ph
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:7/11/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) has ... Testing Market - Forecasts to 2019: Expected to ... is expected to be valued at USD 4,943.0 ... http://photos.prnewswire.com/prnh/20130307/600769 The ... according to immunoprotein types which include immunoglobulins, complement ...
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... 10, 2014 Yesterday, former Congressman ... device manufacturing facility. Rep. Kennedy and Dick ... facilitate cutting-edge research in neurological disease and treatment. ... health advocate, Garen Staglin , created One ... fundamental changes that will radically accelerate the development ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2
... Reportlinker.com announces that a new market ... Respiratory Devices - Global ... to 2016 http://www.reportlinker.com/p0240243/Respiratory-Devices---Global-Pipeline-Analysis-Opportunity-Assessment-and-Market-Forecasts-to-2016.html ... Global Pipeline Analysis, Opportunity Assessment and Market ...
... 14 AAIPharma Services Corp., a leading provider of ... announced today that it has appointed Patrick D. Walsh ... equity firm focused exclusively on health care that acquired ... company in 2009, was instrumental in recruiting Mr. Walsh ...
Cached Medicine Technology:Reportlinker Adds Respiratory Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Reportlinker Adds Respiratory Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer 2AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer 3
(Date:7/12/2014)... 2014 A recent article released by Seattle's ... of suggestions for those seeking cosmetic surgical procedures in ... approaching and the heat begins to enliven the rainy Pacific ... clothing, realizing that they didn’t work out as much during ... cause a sudden surge of people eager to look their ...
(Date:7/12/2014)... FL (PRWEB) July 12, 2014 Maxim ... high-quality peptides that are used solely in scientific experiments, ... two successful years in business, Maxim Peptide, which was ... just launched a new and updated website that now ... blog section has been updated with fascinating articles about ...
(Date:7/11/2014)... Va. (PRWEB) July 11, 2014 The ... at America’s 55 poison centers are commending Senator Bill ... Poison Prevention Act of 2014 on July 10, 2014. ... U.S. Consumer Products Safety Commission (CPSC) to enact rules ... to consumers. , Senate co-sponsors of the ...
(Date:7/11/2014)... Reducing the number of deer in an area can ... tick-borne infections among people, new research indicates. "Our ... reduce human interactions with deer, infected nymphal ticks and ... White-tailed deer are the primary host for adult ... The study included nearly all the permanent residents of ...
(Date:7/11/2014)... York, NY (PRWEB) July 11, 2014 ... http://www.gynecaremorcellatorlawsuit.com/ ) investigation, Bernstein Liebhard LLP has been ... Food & Drug Administration’s (FDA) Obstetrics and ... explore ways to mitigate the cancer risks associated ... invasive gynecological surgeries. According to a report published ...
Breaking Medicine News(10 mins):Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4
... Day of Fall, September 22, Focuses on Preventing ... Today Congress issued,another call to action urging government, ... prevent the increasing number of falls,among people 65 ... (D-MD),and Mike Enzi (R-WY), as well as Representatives ...
... the 2006 Medicare Current Beneficiary Survey, WASHINGTON, ... option for low and moderate income seniors and ... data from the Medicare,Current Beneficiary Survey (MCBS)., ... and those,living in rural areas, rely on Medigap ...
... Olympic Games Champion Nikki Stone and Chronic Pain ... 22 The American Society of Pain,Educators (ASPE) ... Is Your Persistent Chronic Pain Weighing You Down? ... of proper,weight control in managing chronic pain., ...
... therapy delivered in only a week , , MONDAY, Sept. ... radiosurgery may be a viable treatment for recurring pancreatic ... Center, using their precise CyberKnife to perform radiosurgery, had ... the date of treatment. The range of survival was ...
... babies. , Now, it appears how infants respond to stress ... certain gene, according to a new study from the University of ... say they have also found that good parenting as early ... counter the effect the gene has in babies who initially do ...
... Enables SPECT Procedures ... New ASNC Technology Standards, POWAY, Calif., Sept. 22 ... imaging systems and,services to physicians, offices, hospitals and other medical ... Drug,Administration (FDA) 510(k) clearance for its new nSPEED(R) reconstruction,software -- ...
Cached Medicine News:Health News:Home Safety Council(R) Applauds Creation of Falls Prevention Awareness Day 2Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 2Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 3Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 4Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 5Health News:Radiosurgery Proves Viable for Some Pancreatic Cancers 2Health News:UNC study: Parenting can override effect of genes in how babies respond to stress 2Health News:Digirad Corporation Receives FDA 510(k) Clearance for nSPEED(R) Reconstruction Software for Improved Image Quality in Less Time With Less Radiation 2Health News:Digirad Corporation Receives FDA 510(k) Clearance for nSPEED(R) Reconstruction Software for Improved Image Quality in Less Time With Less Radiation 3
... for vascular treatments, Smart VS is the most ... fast amortisation of the investment made. Like all ... with a polarised light viewing system for ensuing ... as well as the operators maximum comfort. I ...
... is an exceptional condensate of ... dimensions for ensuring a rational ... constantly evolving professional market. PhotoLight ... in different studios who require ...
... 2000 system is a pulsed DYE laser ... specific pathologies like Port Wine Stains (PWS), ... pathologies of the trunk and the face. ... all these pathologies, the DYE laser naturally ...
... Plus is a CO2 laser system ... W. Its functions in continuous and ... requiring extreme laser intervention delicacy. Excellent ... studios, it comes with a large ...
Medicine Products: